Contrarius Investment Management’s Biogen BIIB Stock Holding History

Contrarius Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-17,224	Closed	-$4.82M	–	64
2021 Q1	$4.82M	Buy	+17,224	New	+$4.65M	0.27%	44
2018 Q4	–	Sell	-24,329	Closed	-$8.6M	–	48
2018 Q3	$8.6M	Buy	24,329 +6,681	+38%	+$2.3M	0.38%	33
2018 Q2	$5.12M	Buy	17,648 +6	+0%	+$1.69K	0.2%	48
2018 Q1	$4.83M	Buy	17,642 +2,439	+16%	+$757K	0.23%	46
2017 Q4	$4.84M	Sell	15,203 -100,137	-87%	-$32.1M	0.24%	43
2017 Q3	$36.1M	Buy	+115,340	New	+$34.2M	2.11%	15

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Contrarius Investment Management's BIIB Position: Q2 2021 in Review

Contrarius Investment Management sold out of Biogen (BIIB) in Q2 2021, closing a stake of 17,224 shares — an estimated $4.82M sold.

Contrarius Investment Management first reported a position in BIIB in Q3 2017 and held it in 6 quarters. The position peaked at $36.1M in Q3 2017. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Contrarius Investment Management reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Contrarius Investment Management sold 17,224 Biogen shares in Q2 2021, an estimated $4.82M.
Contrarius Investment Management first reported a position in Biogen in Q3 2017 and held it in 6 quarters.
Contrarius Investment Management's Biogen position peaked at $36.1M in Q3 2017.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Contrarius Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.